 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
23 News |  |
- | UCART CS1 / Cellectis
Preclinical, Journal, CAR T-Cell Therapy, IO biomarker: Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma. (Pubmed Central) - Jul 31, 2024
These results demonstrate that UCARTCS1 has potent anti-MM activity against MM cell lines and primary MM cells, as well as in an MM xenograft model and support the evaluation of UCARTCS1 in patients with advanced MM.
- UCART CS1 / Cellectis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Sep 22, 2023
P1, N=11, Terminated, Sponsor: Cellectis S.A.
These results demonstrate that UCARTCS1 has potent anti-MM activity against MM cell lines and primary MM cells, as well as in an MM xenograft model and support the evaluation of UCARTCS1 in patients with advanced MM. N=18 --> 11 | Trial completion date: Dec 2024 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jun 2023; The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.
- | UCART CS1 / Cellectis
Trial primary completion date: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Mar 29, 2023
P1, N=18, Recruiting, Sponsor: Cellectis S.A.
N=18 --> 11 | Trial completion date: Dec 2024 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Jun 2023; The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. Trial primary completion date: Dec 2023 --> Jun 2024
- | UCART CS1 / Cellectis
Trial completion date, Trial primary completion date: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Aug 31, 2022
P1, N=18, Recruiting, Sponsor: Cellectis S.A.
Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Nov 2022 --> Dec 2024 | Trial primary completion date: May 2022 --> Dec 2023
- | UCART CS1 / Cellectis
Trial primary completion date: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Apr 29, 2021
P1, N=18, Recruiting, Sponsor: Cellectis S.A.
Trial completion date: Nov 2022 --> Dec 2024 | Trial primary completion date: May 2022 --> Dec 2023 Trial primary completion date: Nov 2022 --> May 2022
- || UCART CS1 / Cellectis
Enrollment open: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Nov 20, 2020
P1, N=18, Recruiting, Sponsor: Cellectis S.A.
Trial primary completion date: Nov 2022 --> May 2022 Active, not recruiting --> Recruiting
- |||| UCART CS1 / Cellectis
Clinical: FDA Lifts Clinical Hold on MELANI-01 Trial With CAR T Product UCARTCS1 in Myeloma https://t.co/N1Dz372OZf #mmsm (Twitter) - Nov 18, 2020
- ||||| UCART CS1 / Cellectis
Clinical: FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma https://t.co/YeCYrcE0Qn #fda (Twitter) - Nov 17, 2020
- || UCART CS1 / Cellectis
Enrollment closed: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Aug 21, 2020
P1, N=18, Active, not recruiting, Sponsor: Cellectis S.A.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- || UCART CS1 / Cellectis
Clinical: Last time I heard about $CLLS UCARTCS1. Not sure how UCARTCS1A (now on US clinical hold) differs. (Twitter) - Jul 6, 2020
- || UCART CS1 / Cellectis
New P1 trial: Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (clinicaltrials.gov) - Nov 14, 2019
P1, N=18, Recruiting, Sponsor: Cellectis S.A.